Literature DB >> 22246873

Necrotizing myopathy: clinicoserologic associations.

Elizabeth Ellis1, Ju Ann Tan, Sue Lester, Graeme Tucker, Peter Blumbergs, Peter Roberts-Thomson, Vidya Limaye.   

Abstract

INTRODUCTION: Necrotizing myopathy (NM) is distinguished from idiopathic inflammatory myositis (IIM) by dominance of myofiber necrosis, lack of mononuclear inflammatory infiltrates, and presence of antibodies to signal recognition particle (SRP).
METHODS: The clinical features of 64 cases of NM were determined. Measurement of autoantibodies was undertaken on stored sera from 23 patients with NM. The incidence of malignancy was determined from the South Australian Cancer Registry.
RESULTS: NM patients showed male predominance (61%), more frequent myalgias, and higher creatine kinase (CK) levels compared with IIM patients. Patients with NM had a high incidence of systemic lupus erythematosus (SLE) (21%), hypertension (11 of 17, 65%), and diabetes mellitus (3 of 13, 23%). No patient had antibodies to SRP. NM patients showed no altered risk for malignancy compared with the South Australian population (P = 0.86).
CONCLUSIONS: NM is associated with SLE, hypertension, and diabetes mellitus. Comprehensive assessment of cardiovascular risk is indicated in NM, which raises the possibility of targeted interventions.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246873     DOI: 10.1002/mus.22279

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

Review 1.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

Review 2.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 3.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

4.  Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure.

Authors:  O Shovman; B Gilburd; C Chayat; A Dortort Lazar; H Amital; M Blank; C Bentow; M Mahler; Y Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 5.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 6.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 7.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

8.  Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Oscar Pizano-Martinez; Alejandra Ramos-Hernandez; Lilia Andrade-Ortega; Edy-David Rubio-Arellano; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 9.  Neurological Complications in Patients with Systemic Lupus Erythematosus.

Authors:  Amir Shaban; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 6.030

Review 10.  Idiopathic Inflammatory Myopathies: Clinical Approach and Management.

Authors:  Asma Malik; Ghazala Hayat; Junaid S Kalia; Miguel A Guzman
Journal:  Front Neurol       Date:  2016-05-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.